All three cohorts of a phase 1 clinical trial of patients with wet age-related macular degeneration demonstrated positive 30-day safety results, according to a press release from EyePoint Pharmaceuticals.
The DAVIO trial enrolled 17 patients who received one of three doses of EYP-1901 (Durasert sustained-release technology with vorolanib), a twice-yearly intravitreal anti-VEGF treatment.
Through 30 days of post-dosing follow-up, there were no serious adverse events reported, the release said. Additionally, there were no reported adverse events related to significant intraocular inflammation,